Financial Performance - In 2023, the company incurred net losses of 338.1million,366.1 million in 2022, and 182.1millionin2021,indicatingahistoryoffinanciallosses[104].−In2023,thecompany′snetrevenuesdecreasedto343.4 million from 418.9millionintheprioryear,representingan18.01.8 million related to workforce reductions, which affected about 65 employees, or approximately 19% of the global non-production workforce [108]. - The company recorded an incremental provision for excess and obsolete inventory of 38.0millioninQ42023,primarilyduetotheGlobalOperationsReview[118].MarketDemandandSales−Thevolumeofproductssolddecreasedby8.11.3 billion in consolidated indebtedness and other liabilities [237]. - The company issued a total of $1.15 billion in 0% Convertible Senior Notes due 2027 in a private placement [238]. - The company may incur additional indebtedness to meet future financing needs, which could limit cash flow available for operations [239]. - The company may not have sufficient funds to repurchase its Convertible Senior Notes or pay cash upon conversion when required, leading to potential defaults [241]. Intellectual Property and Innovation - The company has three issued patents in the U.S. and ten issued patents internationally, with additional pending applications, highlighting its focus on intellectual property protection [218]. - The company is continuously testing alternative plant-based proteins to enhance product quality and appeal [191]. - The company’s ability to protect its proprietary technology is crucial for its commercial success, but legal protections may be limited [218]. Stock Market and Investor Relations - The market price of the company's stock has been highly volatile, influenced by various economic and competitive factors [283]. - The company has never paid dividends on its capital stock and does not intend to do so in the foreseeable future, relying on price appreciation for investor gains [288]. - Future sales or issuances of common stock could lead to a decline in the market price of the company's common stock [286]. - The trading market for the company's common stock is influenced by analysts' opinions; adverse reports could lead to a decline in share price and trading volume [287].